Voting Rights and Shares Capital of the Company
Nanobiotix, a company listed on Euronext Paris and Nasdaq, has released its monthly report on voting rights and shares capital as of July 31, 2024. The report, in compliance with French regulatory requirements, reveals the following key figures:
• Number of Shares Outstanding: 47,426,851
• Total Theoretical Voting Rights: 49,200,912
• Total Exercisable Voting Rights: 49,178,794
This disclosure is part of Nanobiotix's commitment to transparency and adherence to French financial regulations. The company trades under the ticker NBTX on Nasdaq and is part of Euronext Paris Compartment B.
Nanobiotix, un'azienda quotata su Euronext Paris e Nasdaq, ha pubblicato il suo rapporto mensile sui diritti di voto e sul capitale azionario al 31 luglio 2024. Il rapporto, in conformità con i requisiti normativi francesi, rivela i seguenti dati chiave:
• Numero di Azioni Emesse: 47.426.851
• Diritti di Voto Teorici Totali: 49.200.912
• Diritti di Voto Esercitabili Totali: 49.178.794
Questa comunicazione fa parte del impegno di Nanobiotix per la trasparenza e il rispetto delle normative finanziarie francesi. L'azienda è quotata con il simbolo NBTX su Nasdaq ed è parte del Comparto B di Euronext Paris.
Nanobiotix, una empresa que cotiza en Euronext París y Nasdaq, ha publicado su informe mensual sobre derechos de voto y capital social al 31 de julio de 2024. El informe, en cumplimiento de los requisitos regulatorios franceses, revela las siguientes cifras clave:
• Número de Acciones en Circulación: 47.426.851
• Derechos de Voto Teóricos Totales: 49.200.912
• Derechos de Voto Ejercitables Totales: 49.178.794
Esta divulgación es parte del compromiso de Nanobiotix con la transparencia y la adherencia a las regulaciones financieras francesas. La empresa cotiza bajo el símbolo NBTX en Nasdaq y es parte del Compartimento B de Euronext París.
나노바이오틱스(Nanobiotix)는 파리 유로넥스트(Euronext Paris)와 나스닥(Nasdaq)에 상장된 회사로, 2024년 7월 31일 기준의 의결권 및 자본 주식에 관한 월간 보고서를 발표했습니다. 이 보고서는 프랑스 규제 요건을 준수하며 다음과 같은 주요 수치를 공개했습니다:
• 발행 주식 수: 47,426,851주
• 총 이론적 의결권: 49,200,912권
• 총 행사 가능한 의결권: 49,178,794권
이번 공시는 나노바이오틱스의 투명성에 대한 약속과 프랑스 금융 규제를 준수하고자 하는 의지를 반영합니다. 이 회사는 나스닥에서 NBTX라는 티커로 거래되며, 파리 유로넥스트 B 분류에 포함되어 있습니다.
Nanobiotix, une entreprise cotée sur Euronext Paris et Nasdaq, a publié son rapport mensuel sur les droits de vote et le capital social au 31 juillet 2024. Ce rapport, conformément aux exigences réglementaires françaises, révèle les chiffres clés suivants :
• Nombre d'Actions Outstanding : 47.426.851
• Droits de Vote Théoriques Totaux : 49.200.912
• Droits de Vote Exerçables Totaux : 49.178.794
Cette divulgation fait partie de l'engagement de Nanobiotix pour la transparence et le respect des réglementations financières françaises. L'entreprise est cotée sous le ticker NBTX sur Nasdaq et fait partie du Compartiment B d'Euronext Paris.
Nanobiotix, ein Unternehmen, das an der Euronext Paris und Nasdaq gelistet ist, hat seinen monatlichen Bericht über Stimmrechte und Aktienkapital zum 31. Juli 2024 veröffentlicht. Der Bericht, der den französischen regulatorischen Anforderungen entspricht, zeigt die folgenden wichtigen Zahlen:
• Anzahl der ausgegebenen Aktien: 47.426.851
• Gesamtbetrag der theoretischen Stimmrechte: 49.200.912
• Gesamtbetrag der ausübbaren Stimmrechte: 49.178.794
Diese Offenlegung ist Teil des Engagements von Nanobiotix für Transparenz und Einhaltung der französischen Finanzvorschriften. Das Unternehmen wird unter dem Ticker NBTX an der Nasdaq gehandelt und gehört zur Euronext Paris Kategorie B.
- None.
- None.
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Aug. 08, 2024 (GLOBE NEWSWIRE) --
Paris, France, August 8, 2024
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| July 31, 2024 | 47,426,851 | 49,200,912 | 49,178,794 |
According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
Attachment
FAQ
What is Nanobiotix's total number of outstanding shares as of July 31, 2024?
How many total theoretical voting rights does Nanobiotix (NBTX) have?
What is the difference between Nanobiotix's theoretical and exercisable voting rights?
On which stock exchanges is Nanobiotix (NBTX) listed?
